Format

Send to

Choose Destination
ACS Chem Neurosci. 2019 Feb 20;10(2):792-802. doi: 10.1021/acschemneuro.8b00356. Epub 2019 Feb 11.

Balancing Apoptosis and Autophagy for Parkinson's Disease Therapy: Targeting BCL-2.

Author information

1
Department of Neurobiology School of Basic Medical Sciences, Capital Medical University, Center of Parkinson's Disease Beijing Institute for Brain Disorders, Beijing Key Laboratory of Neural Regeneration and Repair, Beijing Key Laboratory on Parkinson's Disease, Key Laboratory for Neurodegenerative Disease of the Ministry of Education, Beijing 100069 , China.

Abstract

Apoptosis and autophagy are important intracellular processes that maintain organism homeostasis and promote survival. Autophagy selectively degrades damaged cellular organelles and protein aggregates, while apoptosis removes damaged or aged cells. Maintaining a balance between autophagy and apoptosis is critical for cell fate, especially for long-lived cells such as neurons. Conversely, their imbalance is associated with neurodegenerative diseases such as Parkinson's disease (PD), which is characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Restoring the balance between autophagy and apoptosis is a promising strategy for the treatment of PD. Some core proteins engage in cross talk between apoptosis and autophagy, including B cell lymphoma (BCL)-2 family members. This Review summarizes the role of BCL-2 members in the regulation of apoptosis and autophagy and discusses potential therapeutic approaches that target this balance for PD treatment.

KEYWORDS:

Apoptosis; BCL-2; BECN1; Parkinson’s disease; autophagy

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center